MedKoo's

Anticancer molecular libraries

JAK inhibitors

( Janus Kinase Inhibitors)

The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Inclusion of JAK1/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to overcome some of these barriers, resulting in greater success with HCT for MF. (source: Blood. 2012 Aug 16;120(7):1367-79. ).

AG-490 (JAK inhibitor)

AT9283 (JAK inhibitor)

Atiprimod (JAK2 inhibitor)

AZ 960 (JAK inhibitor)

AZD1480 (JAK inhibitor)

CEP-33779 (JAK2 inhibitor)

CYT387 (JAK inhibitor)

EXEL-8232 (JAK2 inhibitor)

INCB20 (JAK inhibitor)

INCB16562 (JAK inhibitor)

Lestaurtinib (CEP701)  (JAK inhibitor)

LY2784544 (JAK inhibitor)

NVP-BSK805 (JAK inhibitor)

Pacritinib (SB1518) (JAK inhibitor)

R348 (JAK inhibitor)

R723 (JAK inhibitor)

Ruxolitinib (INCB018424) (JAK inhibitor)

TG101209 (JAK inhibitor)

TG-101348 (SAR302503) (JAK inhibitor)

Tofacitinib (CP-690550) (JAK inhibitor)

WHI-P154 (Janex-1) JAK inhibitor)

WP-1034 (JAK inhibitor)

WP-1066 (JAK inhibitor)